ANRS | Emerging Infectious Diseases was founded on January 1, 2021 and is an independent agency of Inserm, the French national institute of health and medical research. The Agency’s objectives are to facilitate, evaluate, coordinate, and fund research into HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis, and emerging and re-emerging infectious diseases.
With almost 90% of the ANRS | Emerging Infectious Diseases budget dedicated to research, its work focuses on innovation and strengthening international partnerships through global networks of researchers and health professionals, research organisations, universities, hospitals and associations.
“Being part of a global network of partners funding research into emerging infectious diseases is crucial to an agency such as ANRS | Emerging Infectious Diseases. The COVID-19 pandemic has highlighted the need to improve research coordination. That is why we must join forces across borders if we are to fight emerging diseases effectively. The action we take together and the tools we use will make a difference.”
Prof. Yazdan Yazdanpanah, Director of ANRS | Emerging Infectious Diseases
Scientific coordination, facilitation, evaluation and funding for research into HIV/AIDS, viral hepatitis, STIs, tuberculosis, and emerging and re-emerging infectious diseases.
As part of the French COVID-19 research coordination mechanism, ANRS | Emerging Infectious Diseases provides the framework to prioritize and fast-track studies with strong potential. Two bodies have been set up to achieve this:
ANRS|EID’s COVID-19 Scientific Committee:
CAPNET, an ad hoc national steering committee for therapeutic clinical trials and other COVID-19 research:
In 2021, €51M was dedicated to urgent research on COVID-19. Ten projects, representing an investment of €3M, resulted from a Long Covid CFP. In addition, €45M was dedicated to CFPs on HIV/AIDS, viral hepatitis, STIs and tuberculosis. Numerous working groups have been set up within the Agency to facilitate transdisciplinary COVID-19 research.
The Agency participates in the French government committee to evaluate COVID-19 vaccine candidates and in the pre-clinical study group (GEPC) alongside other academic research players to prioritize therapeutic and/or preventive candidate vaccines for evaluation in pre-clinical studies.
Since 2020, over 40 COVID-19 research projects have been funded in LMICs. Of all the active international projects in 2021, research projects on COVID-19 represented one third of the projects funded or sponsored by the Agency (see graph).
The COVID-19 Task Force in LMICs was created by the Agency and the French Research Institute for Development (IRD) to coordinate research projects carried out by French organizations with their foreign partner institutions in LMICs. The aim of the Task Force is to enable continuous information sharing between the different partners and to propose a coordinated research strategy that responds to the needs and challenges of the on-going SARS COV 2 pandemic.
To better understand, prevent and control emerging infectious diseases at both the national and global level, the Agency is leading 2 national programs:
ANRS | Emerging Infectious Diseases is active in the following international initiatives:
ANRS | Emerging Infectious Diseases works with national authorities at eight partner sites in LMICs: Brazil, Burkina-Faso, Cambodia, Cameroon, Côte d’Ivoire, Egypt, Senegal and Vietnam. The aim is to better manage public health needs identified at local level, implement public health policies in line with those needs, and develop the means to rapidly respond to any emerging diseases. Two-thirds of the active research projects in LMICs are conducted at these sites. The Agency:
ANRS | Emerging Infectious Diseases also has close collaborative partnerships in:
Inserm, and today ANRS | Emerging infectious diseases, were founding members of GloPID-R and have been represented on the Executive Board since 2013. The Director of ANRS | Emerging infectious diseases, Prof. Yazdan Yazdanpanah, has been an active member of the Scientific Advisory Group and is a GloPID-R co-chair. The Agency is particularly invested in GloPID-R’s Data Sharing Working Group and Clinical Trials Network Working Group. It contributes to, and is a user of, the GloPID Research Project Tracker, particularly to inform the national COVID-19 Task Force and to map French research conducted in LMICs. To improve preparedness and response to emerging infectious diseases on a global scale, the Agency is contributing to GloPID-R’s regional hub strategy, beginning in South-East Asia, working with the National Research Foundation (NRF) and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and the Japan Agency for Medical Research and Development (AMED).
Infectious Diseases Now
Clinical Microbiology and Infection
The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.